Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Repatha Monthly Dose Approved With On-Body Pushtronex System

Executive Summary

Amgen’s PCSK9 blocker was cleared by FDA at a 420mg dose that can be administered once monthly via a hands-free device, offering a point of differentiation versus Sanofi/Regeneron’s Praluent.

Advertisement

Related Content

Amgen Plugs Away On Repatha, With Hope For New Monthly Product
Keeping Track: Xiidra, New Repatha Regimen Approved; Abuse-Deterrent Opioid Gets Negative, But Timely, Response
Regeneron: PCSK9s Drowning In Paperwork
Pfizer inSPIREd By Late-Stage PCSK9 Data

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register